Talk:Eli Lilly and Company
|This is the talk page for discussing improvements to the Eli Lilly and Company article.
This is not a forum for general discussion of the article's subject.
|This article is of interest to the following WikiProjects:|
Hello fellow Wikipedians,
I have just modified one external link on Eli Lilly and Company. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
- Added archive https://web.archive.org/web/20080916100937/http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883 to http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883
When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at
You may set the
|checked=, on this template, to true or failed to let other editors know you reviewed the change. If you find any errors, please use the tools below to fix them or call an editor by setting
|needhelp= to your help request.
- If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
- If you found an error with any archives or the URLs themselves, you can fix them with this tool.
If you are unable to use these tools, you may set
|needhelp=<your help request> on this template to request help from an experienced user. Please include details about your problem, to help other editors.
moved this list here, per WP:NOTCATALOG and b/c most of this is not sourced. Per WP:BURDEN please do not restore without finding reliable independent sources, checking this against them, and citing them. pls also consider WEIGHT
- Additional Eli Lilly drugs
- Alimta (for pleural mesothelioma and non-small cell lung cancer).
- Amytal (a "barbituric acid derivative" introduced in 1925 was "the first American sedative of this kind").
- Bavencio (a "barbituric acid derivative avelumab injection" introduced in 2017 was "the first American sedative of this kind") (in conjunction with EMD Serono and Pfizer) Distribution in Canada.
- Ceclor (an oral cephalosporin antibiotic).
- Cambia (for the treatment of migraine).
- Darvocet (an analgesic for mild to moderate pain).
- Darvon, (an analgesic alternative to codeine, introduced in 1957 withdrawn in 2009).
- Effient (an antithrombotic for acute coronary syndrome in percutaneous coronary intervention); co-marketed with Daiichi Sankyo.
- Ephedrine (introduced in 1926 for the treatment of allergies, including hay fever and asthma).
- E-Mycin (an antibiotic for respiratory and other infections).
- Erbitux (for metastatic colorectal cancer and head and neck cancer).
- Evista (for the prevention and treatment of osteoporosis and for the reduction in risk of breast cancer).
- Forteo (for osteoporosis).
- Glucagon (for severe, life-threatening hypoglycemia).
- Humalog (for Type 1 and Type 2 diabetes).
- Humatrope (a human growth hormone for pediatric growth disorders).
- Humulin (for Type 1 and Type 2 diabetes).
- Jardiance (Empagliflozin) (Sodium-glucose co-transporter-2 (SGLT2) inhibitor) (Treats type 2 diabetes: lowers blood sugar, reduces body weight, lowers systolic blood pressure, and reduces cardiac death.
- Keflex (a cephalosporin antibiotic).
- Livalo (for hypercholesterolemia).
- Lipofen (for Mesothelioma, hypercholesterolemia) and Hepatitis B).
- Moxam (an antibiotic. Introduced in collaboration with Shionogi, a Japanese drug company).
- Mandol (an injectable cephalosporin antibiotic for treating "hospital-acquired infections").
- ReoPro (a cardiovascular drug used during high-risk angioplasty surgery).
- Strattera (a non-stimulant medication for attention-deficit hyperactivity disorder).
- Symbyax (for bipolar disorder).
- Tradjenta (for Type 2 diabetes).
- Vascepa (for severe sepsis) Allergic to Fish and osteoporosis) Introduced in collaboration with Amarin Corporation and Kowa Pharma,a Japanese drug company).
- Xigris (for severe sepsis). Withdrawn in November 2011 after failure to show benefit.